Home / Pharmaceuticals / Osteoarthritis Treatment Market By Type (Analgesics, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Hyaluronic Acid, Pipeline Analysis) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Osteoarthritis Treatment Market By Type (Analgesics, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Hyaluronic Acid, Pipeline Analysis) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Published: May 2016 | Report Code: 57819-05-16

This report on global osteoarthritis treatment market studies various type of therapeutics used for treatment of osteoarthritis along with pipeline analysis of upcoming potential drugs. Globally, osteoarthritis is the eighth leading cause of disability with the joint most frequently associated with disability being the knee. The current treatment available for osteoarthritis treatment is incapable due to lack of efficacy and serious side-effects associated with the long term use. Thus, drug pipeline of osteoporosis treatment market comprises potential drugs which possesses high efficacy, less side-effects and innovative properties. 

For the purpose of this study, the various therapeutics type considered are analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and hyaluronic acid. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Osteoarthritis Treatment Market 

The pipeline analysis for osteoarthritis treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Sprifermin (Merck Serono), Invossa (TissueGene), Ampion (Ampio Pharmaceuticals. Inc.),Apitox (Apimeds, Inc.), Fasinumab (Regeneron Pharmaceuticals), LBSA0103 (LG Life Sciences), and AXS-02 (Axsome Therapeutics, Inc.). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global osteoarthritis treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The key players covered in osteoarthritis treatment market are Abbott Laboratories, Johnson & Johnson Limited, Novartis AG, Pfizer, Inc., Abiogen Pharma Spa, Ampio Pharmaceuticals, BioDelivery Sciences International, Inc., Eli Lilly and Company, Merck & Co., Sanofi SA, and Smith & Nephew, Inc.

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Osteoarthritis TreatmentMarket Portaiture
2.2 Global Osteoarthritis Treatment Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Osteoarthritis Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Osteoarthritis Treatment Market: Market Dynamics and Outlook
3.1 Osteoarthritis Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Osteoarthritis Treatment Market, 2015 (Value %)

Chapter 4 Global Osteoarthritis Treatment Market, By Type of Therapeutics
4.1 Preface
4.2 Analgesics
4.3 Non-steroidal anti-inflammatory drugs (NSAIDs)
4.4 Corticosteroids
4.5 Hyaluronic Acid
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 Sprifermin
4.6.1.2 Invossa
4.6.1.3 Ampion
4.6.1.4 Apitox
4.6.1.5 Fasinumab
4.6.1.6 LBSA0103
4.6.1.7 AXS-02
4.6.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Osteoarthritis Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 BioDelivery Sciences International, Inc.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
v.3.4 News Coverage
6.4 Abiogen Pharma Spa
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Johnson & Johnson Limited
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Abbott Laboratories
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Eli Lilly and Company
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Sanofi SA
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Merck & Co.
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Smith & Nephew, Inc.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List of Figures

FIG 1 Global Osteoarthritis Treatment Market, by Drugs, 2015 (USD Mn)
FIG 2 Relativity Analysis: Global Osteoarthritis Treatment Market, by Geography, 2015 & 2022 (USD Mn)
FIG 3 Attractive Investment Proposition, Global Osteoarthritis Treatment Market, 2015
FIG 4 Market Share Analysis: Global Osteoarthritis Treatment Market, 2015 (Value %)
FIG 5 Global Analgesics Market for Osteoarthritis Treatment, 2013 – 2022 (USD Mn)
FIG 6 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market for Osteoarthritis Treatment, 20137– 2022 (USD Mn)
FIG 7 Global Corticosteroids Market for Osteoarthritis Treatment, 2013 –2022 (USD Mn)
FIG 8 Global Hyaluronic Acid Market for Osteoarthritis Treatment, 2013 – 2022 (USD Mn)
FIG 9 Pipeline Analysis: Global Sprifermin Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
FIG 10 Pipeline Analysis: Global Invossa Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
FIG 11 Pipeline Analysis: Global Ampion Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
FIG 12 Pipeline Analysis: Global Apitox Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
FIG 13 Pipeline Analysis: Global Fasinumab Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
FIG 14 Pipeline Analysis: Global LBSA0103 Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
FIG 15 Pipeline Analysis: Global AXS-02 Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
FIG 16 U.S. Osteoarthritis Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 17 Canada Osteoarthritis Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 18 U.K Osteoarthritis TreatmentMarket Revenue, 2013 – 2022 (USD Mn)
FIG 19 Germany Osteoarthritis Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 20 Rest of Europe Osteoarthritis Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 21 China Osteoarthritis Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 22 Japan Osteoarthritis Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 23 Rest of Asia Pacific Osteoarthritis Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 24 Latin America Osteoarthritis Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 25 Middle East and Africa Osteoarthritis Treatment Market Revenue, 2013 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Osteoarthritis Treatment Market Revenue, by Type of Therapeutics, 2013 – 2022 (USD Mn)
TABLE 2 Global Osteoarthritis Treatment Market Revenue, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Osteoarthritis Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Osteoarthritis Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia - Pacific Osteoarthritis Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 6 Rest of the World Osteoarthritis Treatment Market Revenue, by Region, 2013 – 2022 (USD Mn)

Type of Therapeutics Segmentation Analysis

According to Arthritis Foundation, osteoarthritis is a chronic (long-term) disease with no cure, but treatments are available to manage symptoms. The National Institute of Aging suggests that osteoarthritis treatment include several ways to manage pain and improve function with the help of exercise, rest and joint care, pain relief, weight control, medicines, surgery, and non-traditional treatment approaches. Based on the type of therapeutics, the osteoarthritis treatment market is segmented into:

  • Analgesics
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Corticosteroids
  •  Hyaluronic Acid

Osteoarthritis Treatment Market

A combined data extracted from published report of Centers for Disease Control and Prevention (CDC) and National Health Interview Survey (NHIS) suggests that, in the U.S. overall 22.7% (52.5 million) of adults reported doctor-diagnosed arthritis, with significantly higher age-adjusted prevalence in 2010 - 2012 it was observed that women (23.9%) patient were more than men (18.6%) patients and arthritis prevalence increases with age. By the year 2040, an estimated 78 million (26% of the projected total adult population) adults aged 18 years and older will have doctor-diagnosed arthritis, compared with the 52.5 million adults in 2010 - 2012. In base year 2015, the NSAIDs and corticosteroids collectively attribute the largest share in the market in terms of revenue (USD). The pain and loss of function can be unbearable; in developed countries the resultant socioeconomic burden is large, costing between 1.0% and 2.5% of gross domestic product. The treatment observed in osteoarthritis has been patient-specific; however, pain management in osteoarthritis is considered as the most important factor which is currently carried out with the help of NSAIDs and corticosteroids as the first choice. However, a recent study published in Lancet by Dr. Sven Trelle, of the University of Bern in Switzerland, covered that acetaminophen (paracetamol) was only marginally better than a placebo for treating symptoms of the degenerative joint disease. Furthermore, diclofenac was observed as the most effective for short-term pain relief from osteoarthritis, though the Dr. Sven Trelle and colleagues recommended against taking the medication long term due to its side effects. Hence, in the near future drugs in pipeline with less side-effects and high efficiency would be responsible for decline in market shares of NSAIDs and corticosteroids in osteoarthritis treatment market.

For the purpose of this study, the global osteoarthritis treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Osteoarthritis Treatment Market

North America was observed as the largest market for osteoarthritis treatment in the base year 2015. According to Centers for Disease Control and Prevention (CDC), in 2015 the U.S. comprises 62% of adults with arthritis are <65 years old and by 2040, an estimated 78 million Americans ages 18 years or older are projected to have doctor-diagnosed arthritis. The key factors driving North America osteoarthritis treatment market are rise in prevalence of aging population, higher acceptance for novel treatments and rising public awareness related to diagnosis of age-specific diseases. The prevalence of osteoarthritis is increasing due to population ageing and an increase in related factors such as obesity. According to the United Nations, by 2050 people aged over 60 will account for more than 20% of the world’s population. Of that 20%, a conservative estimate of 15% will have symptomatic osteoarthritis, and one-third of these people will be severely disabled. This means that by 2050, 130 million people will suffer from osteoarthritis worldwide, of which 40 million will be severely disabled by the disease. Market experts also suggest that, costs associated with osteoarthritis include costs for adaptive aids and devices, medicines, surgery, and time off at work. Thus, globally osteoarthritis treatment market is expected to grow notably throughout the forecast period 2016 – 2022.  

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients